Skip to main content

A Phase 2 Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With Thymidine Kinase 2 Deficiency (TK2)

Open
  • Protocol code: MT-1621-102
  • EudraCT code: 2018-004277-27
  • Research group: Pediatric Neurology
  • Service: General Pediatrics and Specialties
  • Principal investigator:  Munell Casadesus, Francina
  • Phase: Fase II
  • Status: Recruiting volunteers